P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS by S. P. Desikan, G. Montalban-Bravo, M. Ohanian, N. Daver, T. Kadia, S. Venugopal, K. Chien, H. Kantarjian, G. Garcia-Manero

Get full text

P754: INITIAL RESULTS OF PHASE I/II STUDY OF AZACITIDINE IN COMBINATION WITH QUIZARTINIB FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM... by T. Abuasab, E. Jabbour, N. Short, M. Konopleva, K. S. Chien, S. Fareed Mohamed, N. Daver, R. Kanagal-shamanna, G. Garcia-Manero, G. Montalban-Bravo

Get full text

P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML by J. Senapati, F. Haddad, F. Ravandi, T. Kadia, C. DiNardo, N. Daver, N. Pemmaraju, Y. Alvarado, M. A. Brandt, H. Kantarjian, G. Borthakur

Get full text

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34) by F. Ong, T. M. Kadia, N. J. Short, M. Yilmaz, Y. Alvarado, S. Pierce, G. Garcia-Manero, C. DiNardo, G. Borthakur, M. Konopleva, N. Daver, H. Kantarjian, F. Ravandi

Get full text

P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE by T. Abuasab, S. F. Mohadam, H. Hwang, X. Wang, K. Sasaki, M. Yilmaz, T. Kadia, C. DiNardo, N. Daver, N. Pemmaraju, G. Borthakur, F. Ravandi, G. Garcia-Manero, K. Takahashi

Get full text

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC L... by S. Venugopal, H. kantarjian, A. Maiti, N. Short, G. Montalban-Bravo, Y. Alvarado, K. S. Chien, R. Kanagal-Shamanna, N. Pemmaraju, N. Daver, T. Kadia, G. Borthakur, E. Jabbour, G. Garcia-Manero

Get full text

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WIT... by N. Daver, M. Maris, R. Ramchandren, D. Bixby, K. Doucette, R. Mawad, D. Egan, D. Stevens, J. Zonder, N. Molloy, A. Scheuber, I. Bruns, I. Mantzaris, M. Konopleva, A. D. Goldberg

Get full text

P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEM... by A. Bazinet, T. Kadia, N. Short, G. Borthakur, S. Wang, S. Loghavi, J. Jorgensen, K. Patel, C. DiNardo, N. Daver, Y. Alvarado, F. Haddad, S. Pierce, M. Andreeff, E. Jabbour, M. Konopleva, H. Kantarjian, F. Ravandi

Get full text

P1063: EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A P... by A. Yacoub, U. Borate, R. Rampal, H. Ali, E. Wang, A. Gerds, G. Hobbs, M. Kremyanskaya, E. Winton, C. O’Connell, S. Goel, S. Oh, G. Schiller, A. Assad, S. Erickson-Viitanen, F. Zhou, N. Daver

Get full text

P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS by S. Venugopal, E. Jabbour, N. Pemmaraju, G. Montalban-Bravo, K. S. Chien, N. Daver, N. Jain, J. Burger, Y. Alvarado, A. Maiti, C. D. DiNardo, G. Borthakur, R. Malla, G. Garcia-Manero, F. Ravandi, H. Kantarjian, T. Kadia

Get full text

P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS... by T. Abuasab, Y. Alvarado, G. Issa, R. Islam, N. Short, M. Yilmaz, N. jain, L. Masarova, S. Kornblau, E. Jabbour, N. Pemmaraju, G. Montalban-Bravo, S. Pierce, C. DiNardo, T. Kadia, N. Daver, M. Konopleva, G. Garcia-Manero, F. Ravandi

Get full text

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY by M. Yilmaz, M. Muftuoglu, H. Kantarjian, C. DiNardo, T. Kadia, G. Borthakur, N. Pemmaraju, N. Short, Y. Alvarado, A. Maiti, L. Masarova, G. Montalban Bravo, S. Loghavi, K. Patel, S. Kornblau, E. Jabbour, G. Garcia-Manero, M. Andreeff, N. Daver

Get full text

P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS by F. Haddad, K. Sasaki, T. Abuasab, S. Venugopal, D. Rivera Delgado, A. Bazinet, R. Babakhanlou, K. Kim, J. Senapati, F. Ong, S. Desikan, N. Short, N. Pemmaraju, G. Borthakur, C. DiNardo, N. Daver, E. Jabbour, G. Garcia-Manero, F. Ravandi, T. Kadia

Get full text

P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRI... by F. Haddad, H. Kantarjian, N. Short, F. Ravandi, N. Jain, W. Macaron, T. Kadia, Y. Alvarado, N. Daver, G. Borthakur, C. DiNardo, M. Konopleva, W. Wierda, J. Jacob, E. Roy, C. Loiselle, A. Milton, J. Rivera, R. Garris, E. Jabbour

Get full text

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA by J. Senapati, J. Ishizawa, H. A. Abbas, S. Loghavi, G. Borthakur, G. C. Issa, S. I. Dara, R. Pourebrahim, N. Daver, E. J. Jabbour, S. M. Kornblau, N. Pemmaraju, G. Garcia-Manero, F. Ravandi, M. Muftuoglu, J. Khoury, C. DiNardo, M. Andreeff

Get full text

P1203: THE OPTIMIZED HLH INFLAMMATORY (OHI) INDEX IDENTIFIES LYMPHOMA PATIENTS WITH UNEXPECTEDLY HIGH MORTALITY NOT RELATED TO DISEASE PROGRESSION by A. Zoref-Lorenz, J. Murakami, L. Hofstetter, U. Abadi, S. Iyer, S. Mohamed, P. G. Miller, A. E. H. Natour, S. Weinstein, J. Yacobovich, S. Izraeli, S. Nikiforow, B. Ebert, R. Gurion, I. Cohen, O. Pasvolsky, P. Raanani, A. Nagler, N. Berliner, N. Daver, M. Ellis, M. Jordan

Get full text

P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) by F. Ong, F. Ravandi, U. Popat, T. M. Kadia, N. Daver, C. DiNardo, M. Konopleva, G. Borthakur, E. J. Shpall, B. Oran, G. Al-Atrash, R. Mehta, E. J. Jabbour, M. Yilmaz, G. C. Issa, G. Garcia-Manero, A. Maiti, H. A. Abbas, R. E. Champlin, N. J. Short

Get full text

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS by D. A. Sallman, M. M. Al Malki, A. S. Asch, E. S. Wang, J. G. Jurcic, T. J. Bradley, I. W. Flinn, D. A. Pollyea, S. N. Kambhampati, T. N. Tanaka, J. F. Zeidner, G. Garcia-Manero, D. Jeyakumar, L. Gu, A. Tan, M. Chao, C. O’Hear, I. Lal, P. Vyas, N. Daver

Get full text

P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA by A. Bazinet, E. Jabbour, H. Kantarjian, K. Chien, C. DiNardo, M. Ohanian, N. Daver, R. Kanagal-Shamanna, T. Kadia, K. Takahashi, L. Masarova, N. Short, Y. Alvarado, P. Thompson, G. Montalban-Bravo, M. Yilmaz, F. Ravandi, M. Konopleva, M. Andreeff, S. Kornblau, N. Pemmaraju, D. Hammond, H. Schneider, B. Mirabella, G. Garcia-Manero

Get full text